既往抗生素治疗与免疫检查点抑制剂疗效及生存的关联
这项前瞻性多中心队列研究纳入196例接受免疫检查点抑制剂(ICI)治疗的癌症患者,发现既往抗生素治疗(pATB)与更差的总生存(OS)和更高的原发耐药风险相关,而同步抗生素治疗(cATB)无此关联。多因素分析证实pATB是OS的独立不良因素。
要点
- 既往抗生素治疗与接受ICI治疗患者更差的总生存独立相关。
- 既往抗生素治疗与更高比例的原发耐药相关。
- 同步抗生素治疗未显示与总生存或疗效的显著关联。
核心结论
- 在常规临床实践中接受ICI治疗的非选择患者中,既往抗生素治疗而非同步抗生素治疗与更差的治疗反应和总生存相关。
研究设计与样本
- 前瞻性、多中心队列研究,在2个三级学术转诊中心招募196例于2015年1月1日至2018年4月1日接受ICI治疗的癌症患者。
主要发现
- 既往抗生素治疗组中位OS为2个月,无既往抗生素治疗组为26个月(HR 7.4,95%CI 4.3-12.8,P<.001)。
- 既往抗生素治疗组原发耐药比例为21/26(81%),无既往抗生素治疗组为66/151(44%),P<.001。
- 非小细胞肺癌患者中既往抗生素治疗组与无既往抗生素治疗组中位OS分别为2.5个月与26个月(P<.001)。
- 黑色素瘤患者中两组中位OS分别为3.9个月与14个月(P<.001),其他肿瘤类型分别为1.1个月与11个月(P<.001)。
- 多因素分析显示既往抗生素治疗(HR 3.4,95%CI 1.9-6.1,P<.001)和对ICI治疗的反应(HR 8.2,95%CI 4.0-16.9,P<.001)与OS独立相关。
关键数值与推荐
- 总生存从ICI治疗开始计算,影像学反应采用实体瘤疗效评价标准(RECIST)1.1版。
- ICI难治性疾病定义为首次ICI给药后6至8周出现疾病进展且无假性进展证据。
临床怎么用
- 在启动ICI治疗前应审慎评估既往抗生素使用史,因其与更差生存和原发耐药相关。
- 同步使用抗生素未显示与不良生存的关联,但需结合临床情况个体化判断。
局限性
- 样本量有限。
- 地理来源受限。
- 缺乏对患者肠道菌群的相关性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gut dysbiosis impairs response to immune checkpoint inhibitors (ICIs) and can be caused by broad-spectrum antibiotic (ATB) therapy. OBJECTIVE: To evaluate whether there is an association between ATB therapy administered concurrently (cATB) or prior (pATB) to ICI therapy and overall survival (OS) and treatment response to ICI therapy in patients with cancer treated with ICIs in routine clinical practice. DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter, cohort study conducted at 2 tertiary academic referral centers recruited 196 patients with cancer who received ICI therapy between January 1, 2015, and April 1, 2018, in routine clinical practice rather than clinical trials. MAIN OUTCOMES AND MEASURES: Overall survival calculated from the time of ICI therapy commencement and radiologic response to ICI treatment defined using the Response Evaluation Criteria in Solid Tumors (version 1.1), with disease refractory to ICI therapy defined as progressive disease 6 to 8 weeks after the first ICI dose without evidence of pseudoprogression. RESULTS: Among 196 patients (137 men and 59 women; median [range] age, 68 [27-93] years) with non-small cell lung cancer (n = 119), melanoma (n = 38), and other tumor types (n = 39), pATB therapy (HR, 7.4; 95% CI, 4.3-12.8; P < .001), but not cATB therapy (HR, 0.9; 95% CI, 0.5-1.4; P = .76), was associated with worse OS (2 vs 26 months for pATB therapy vs no pATB therapy, respectively) (hazard ratio [HR], 7.4; 95% CI, 4.2-12.9) and a higher likelihood of primary disease refractory to ICI therapy (21 of 26 [81%] vs 66 of 151 [44%], P < .001). Overall survival in patients with non-small cell lung cancer (2.5 vs 26 months, P < .001), melanoma (3.9 vs 14 months, P < .001), and other tumor types (1.1 vs 11, P < .001) was consistently worse in those who received pATBs vs those who did not. Multivariate analyses confirmed that pATB therapy (HR, 3.4; 95% CI, 1.9-6.1; P < .001) and response to ICI therapy (HR, 8.2; 95% CI, 4.0-16.9; P < .001) were associated with OS independent of tumor site, disease burden, and performance status. CONCLUSIONS AND RELEVANCE: Despite being limited by sample size, geographic origin, and the lack of correlative analyses on patients' gut microbiota, this study suggests that pATB therapy but not cATB therapy is associated with a worse treatment response and OS in unselected patients treated with ICIs in routine clinical practice. Mechanistic studies are urgently required to investigate ATB-mediated alterations of gut microbiota as a determinant of poorer outcome following ICI treatment.
引用
- Pinato DJ, Howlett S, Ottaviani D, et al. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol. 2019. PMID: 31513236. doi:10.1001/jamaoncol.2019.2785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。